Show simple item record

TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)

dc.contributor.authorNaini, V.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorYu, M.
dc.contributor.authorDarif, M.
dc.contributor.authorMerseburger, A. S.
dc.contributor.authorChi, K. N.
dc.contributor.authorChowdhury, S.
dc.contributor.authorRadziszewski, P.
dc.contributor.authorLebret, T.
dc.contributor.authorSternberg, C.
dc.contributor.authorSims, R. B.
dc.date.accessioned2021-03-04T19:43:54Z
dc.date.available2021-03-04T19:43:54Z
dc.identifier.citationChi K. N. , Chowdhury S., Radziszewski P., Lebret T., Ozguroglu M., Sternberg C., Sims R. B. , Yu M., Naini V., Darif M., et al., "TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)", 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27
dc.identifier.othervv_1032021
dc.identifier.otherav_9133ac1d-61f4-4143-b640-b31b29619645
dc.identifier.urihttp://hdl.handle.net/20.500.12627/97973
dc.identifier.urihttps://doi.org/10.1093/annonc/mdw372.54
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleTITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)
dc.typeBildiri
dc.contributor.departmentBritish Columbia Cancer Agency , ,
dc.identifier.volume27
dc.contributor.firstauthorID150307


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record